Cited by 281Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchDown syndrome and intellectual disability research

The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between β-amyloid production and tau phosphorylation in Alzheimer disease

Open access
Kimura, Ryo, Kamino, Kouzin, Yamamoto, Mitsuko, Nuripa, Aidaralieva, Kida, Tomoyuki, Kazui, Hiroaki, Hashimoto, Ryota, Tanaka, Toshihisa +13 more·2007·Human Molecular Genetics

Abstract

We scanned throughout chromosome 21 to assess genetic associations with late-onset Alzheimer disease (AD) using 374 Japanese patients and 375 population-based controls, because trisomy 21 is known to be associated with early deposition of beta-amyloid (Abeta) in the brain. Among 417 markers spanning 33 Mb, 22 markers showed associations with either the allele or the genotype frequency (P < 0.05). Logistic regression analysis with age, sex and apolipoprotein E (APOE)-epsilon4 dose supported genetic risk of 17 markers, of which eight markers were linked to the SAMSN1, PRSS7, NCAM2, RUNX1, DYRK1A and KCNJ6 genes. In logistic regression, the DYRK1A (dual-specificity tyrosine-regulated kinase 1A) gene, located in the Down syndrome critical region, showed the highest significance [OR = 2.99 (95% CI: 1.72-5.19), P = 0.001], whereas the RUNX1 gene showed a high odds ratio [OR = 23.3 (95% CI: 2.76-196.5), P = 0.038]. DYRK1A mRNA level in the hippocampus was significantly elevated in patients with AD when compared with pathological controls (P < 0.01). DYRK1A mRNA level was upregulated along with an increase in the Abeta-level in the brain of transgenic mice, overproducing Abeta at 9 months of age. In neuroblastoma cells, Abeta induced an increase in the DYRK1A transcript, which also led to tau phosphorylation at Thr212 under the overexpression of tau. Therefore, the upregulation of DYRK1A transcription results from Abeta loading, further leading to tau phosphorylation. Our result indicates that DYRK1A could be a key molecule bridging between beta-amyloid production and tau phosphorylation in AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/hmg/ddl437

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Many additional genes on HSA21 modulate processes that could contribute to AD pathology in DS.

    “However, many additional genes on HSA21 modulate processes that could contribute to AD pathology in DS.14,15,16”

    From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [14]

    The Discussion (page unavailable) reports AD-associated markers linked to six chromosome 21 genes, and the paper describes how DYRK1A may connect amyloid accumulation to tau phosphorylation. The other genes are discussed mainly through their known functions and genetic associations; the paper does not establish that many of them modulate processes contributing to AD pathology specifically in Down syndrome. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 5

  1. Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Small, G.W., Roses, A.D., Haines, J.L. and Pericak-Vance, M.A. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 261, 921 -923.
  2. Pericak-Vance, M.A., Grubber, J., Bailey, L.R., Hedges, D., West, S., Santoro, L., Kemmerer, B., Hall, J.L., Saunders, A.M., Roses, A.D. et al. (2000) Identification of novel genes in late-onset Alzheimer's disease. Exp. Gerontol., 35, 1343-1352.
  3. Theriault, F.M., Roy, P. and Stifani, S. (2004) AML1/Runx1 is important for the development of hindbrain cholinergic branchiovisceral motor neurons and selected cranial sensory neurons. Proc. Natl Acad. Sci. USA, 101, 10343-10348.
  4. Song, W.J., Sternberg, L.R., Kasten-Sportes, C., Keuren, M.L., Chung, S.H., Slack, A.C., Miller, D.E., Glover, T.W., Chiang, P.W., Lou, L. et al. (1996) Isolation of human and murine homologues of the Drosophila minibrain gene: human homologue maps to 21q22.2 in the Down syndrome 'critical region'. Genomics, 38, 331-339. 22 Human Molecular Genetics, 2007, Vol. 16, No. 1
  5. Guo, J.P., Arai, T., Miklossy, J. and McGeer, P.L. (2006) Ab and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc. Natl Acad. Sci. USA, 103, 1953-1958.

Cited by

Sorted by citations

Authors
Kimura, R., Kamino, K., Yamamoto, M., Nuripa, A., Kida, T., Kazui, H., Hashimoto, R., Tanaka, T., Kudo, T., Yamagata, H., Tabara, Y., Miki, T., Akatsu, H., Kosaka, K., Funakoshi, E., Nishitomi, K., Sakaguchi, G., Kato, A., Hattori, H., Uema, T., & Takeda, M.
Affiliations
  • The University of Osaka (JP)
  • Ehime University (JP)
  • Fukushimura Hospital (JP)
  • Setsunan University (JP)
  • Shionogi (Japan) (JP)
  • Chubu National Hospital (JP)
  • Osaka Prefectural Medical Center (JP)
Corresponding author
Kamino, Kouzin
Venue
Human Molecular Genetics
Published
2006-11-29
Volume
16
Issue
1
Pages
15-23
ISSN
  • 0964-6906 (ISSN-L)
  • 1460-2083
OpenAlex
W2125851351
Cited by
281
References
2
Citations by year
2026: 16 · 2025: 18 · 2024: 7 · 2023: 17 · 2022: 25 · 2021: 22 · 2020: 10 · 2019: 8 · 2018: 12 · 2017: 10 · 2016: 13 · 2015: 17 · 2014: 13 · 2013: 11 · 2012: 15
FWCI
6.64
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Human Molecular Genetics (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Ministry of Education, Culture, Sports, Science and Technology
  • Japan Society for the Promotion of Science
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
Keywords
DYRK1A, late-onset Alzheimer's disease, Down syndrome critical region, chromosome 21, amyloid-beta, tau phosphorylation, genetic association, RUNX1, Down syndrome, hippocampus, transgenic mice, neuroblastoma cells, Japanese patients
MeSH terms
Dyrk Kinases, Aged, Aged, 80 and over, Alzheimer Disease, Animals, Brain, Chromosomes, Human, Pair 21, Down Syndrome, Female, Haplotypes, Humans, Male, Membrane Proteins, Mice, Transgenic, Middle Aged, Phosphorylation, Protein-Tyrosine Kinases, RNA, Messenger, Case-Control Studies, Amyloid beta-Peptides, tau Proteins, Protein Serine-Threonine Kinases, Polymorphism, Single Nucleotide, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review